Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs

Core Insights - Viatris reported third-quarter results that exceeded profit and revenue estimates, attributed to robust demand for its branded drugs in China and emerging markets [1] Company Performance - The strong performance in the third quarter was primarily driven by the sales of branded drugs, indicating a positive market response in key regions [1] Market Dynamics - The demand for Viatris' products in China and emerging markets highlights the potential growth opportunities in these regions, suggesting a favorable environment for pharmaceutical companies [1]